BIOMAT Database Logo BIOMAT Database Logo

Pressor response to saralasin reversed by phentolamine in essential hypertension. 1978

S Takishita, and K Fukiyama, and K Tamaki, and T Omae

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010646 Phentolamine A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease. Fentolamin,Phentolamine Mesilate,Phentolamine Mesylate,Phentolamine Methanesulfonate,Phentolamine Mono-hydrochloride,Regitine,Regityn,Rogitine,Z-Max,Mesilate, Phentolamine,Mesylate, Phentolamine,Methanesulfonate, Phentolamine,Mono-hydrochloride, Phentolamine,Phentolamine Mono hydrochloride
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Diuretic therapy and response of essential hypertension to saralasin.
August 1977, Annals of internal medicine,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Response to saralasin and angiotensin's role in essential and renal hypertension.
March 1979, Medicine,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Plasma catecholamines and the pressor response to saralasin.
April 1977, The New England journal of medicine,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Dogfish pressor response to potassium blocked by magnesium and phentolamine.
March 1982, The American journal of physiology,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Renin, sodium, and vasodepressor response to saralasin in renovascular and essential hypertension.
August 1977, Annals of internal medicine,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
PRESSOR RESPONSE IN ESSENTIAL HYPERTENSION. BLOOD PRESSURE RESPONSE TO NORADRENALINE IN THE PATIENT WITH ESSENTIAL HYPERTENSION.
September 1963, Japanese heart journal,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Pressor response to norepinephrine in essential hypertension. A study in families.
February 1990, Hypertension (Dallas, Tex. : 1979),
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Saralasin infusion in renovascular and essential hypertension.
January 1980, The Netherlands journal of medicine,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects.
March 1977, Circulation research,
S Takishita, and K Fukiyama, and K Tamaki, and T Omae
[Clinical studies on the etiology of essential hypertension. Pressor response to noradrenaline].
January 1965, Sapporo igaku zasshi. The Sapporo medical journal,
Copied contents to your clipboard!